45 Tutorial on LC-MS/MS methods quantifying mAbs 73. Budhraja RH, Shah MA, Suthar M, Yadav A, Shah SP, Kale P, Asvadi P, Valan Arasu M, Al-Dhabi NA, Park CG, Kim YO, Kim HJ, Agrawal YK, Krovidi RK. LC-MS/MS Validation Analysis of Trastuzumab Using dSIL Approach for Evaluating Pharmacokinetics. Molecules. 2016; 21: 1464. 74. Jourdil JF, Lebert D, Gautier-Veyret E, Lemaitre F, Bonaz B, Picard G, Tonini J, Stanke-Labesque F. Infliximab quantitation in human plasma by liquid chromatography-tandem mass spectrometry: towards a standardization of the methods? Anal Bioanal Chem. 2017; 409: 1195-1205. 75. Becher F, Ciccolini J, Imbs DC, Marin C, Fournel C, Dupuis C, Fakhry N, Pourroy B, Ghettas A, Pruvost A, Junot C, Duffaud F, Lacarelle B, Salas S. A simple and rapid LC-MS/MS method for therapeutic drug monitoring of cetuximab: a GPCO-UNICANCER proof of concept study in head-and-neck cancer patients. Sci Rep. 2017; 7: 2714. 76. Chiu HH, Tsai IL, Lu YS, Lin CH, Kuo CH. Development of an LC-MS/MS method with protein G purification strategy for quantifying bevacizumab in human plasma. Anal Bioanal Chem. 2017; 409: 6583-6593. 77. Walpurgis K, Thomas A, Dellanna F, Schanzer W, Thevis M. Detection of the Human Anti-ActRII Antibody Bimagrumab in Serum by Means of Affinity Purification, Tryptic Digestion, and LC-HRMS. Proteomics Clin Appl. 2017; 12: e1700120. 78. Shibata K, Naito T, Okamura J, Hosokawa S, Mineta H, Kawakami J. Simple and rapid LC-MS/MS method for the absolute determination of cetuximab in human serum using an immobilized trypsin. J Pharm Biomed Anal. 2017; 146: 266-272. 79. Dubois M, Fenaille F, Clement G, Lechmann M, Tabet JC, Ezan E, Becher F. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem. 2008; 80: 1737-1745. 80. Legeron R, Xuereb F, Chaignepain S, Gadeau AP, Claverol S, Dupuy JW, Djabarouti S, Couffinhal T, Schmitter JM, Breilh D. A new reliable, transposable and cost-effective assay for absolute quantification of total plasmatic bevacizumab by LC-MS/MS in human plasma comparing two internal standard calibration approaches. J Chromatogr B Analyt Technol Biomed Life Sci. 2017; 1070: 43-53. 81. Chiu HH, Liao HW, Shao YY, Lu YS, Lin CH, Tsai IL, Kuo CH. Development of a general method for quantifying IgG-based therapeutic monoclonal antibodies in human plasma using protein G purification coupled with a two internal standard calibration strategy using LC-MS/MS. Anal Chim Acta. 2018; 1019: 93-102. 82. Jourdil JF, Nemoz B, Gautier-Veyret E, Romero C, Stanke-Labesque F. Simultaneous quantification of adalimumab and infliximab in human plasma by liquid chromatography-tandem mass spectrometry. Ther Drug Monit. 2018; 40: 417-424. 83. Yang Y, Wysocki E, Antwi K, Niederkofler E, Leung EKY, Lazar-Molnar E, Yeo KJ. Development and validation of a targeted affinity-enrichment and LC-MS/MS proteomics approach for the therapeutic monitoring of adalimumab. Clin Chim Acta. 2018; 483: 308-314. 84. Vialaret J, Broutin S, Pugnier C, Santele S, Jaffuel A, Barnes A, Tiers L, Pelletier L, Lehmann S, Paci A, Hirtz C. What sample preparation should be chosen for targeted MS monoclonal antibody quantification in human serum? Bioanalysis. 2018; 10: 723-735. 85. El Amrani M, Szanto CL, Hack CE, Huitema ADR, Nierkens S, van Maarseveen EM. Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry. Anal Bioanal Chem. 2018; 410: 5849-5858. 86. Ren D, Pipes GD, Liu D, Shih LY, Nichols AC, Treuheit MJ, Brems DN, Bondarenko PV. An improved trypsin digestion method minimizes digestion-induced modifications on proteins. Anal Biochem. 2009; 392: 12-21. 2
RkJQdWJsaXNoZXIy MTk4NDMw